

## CLAIMS

5

1. Pharmaceutical composition comprising lipids extracted from the mother of pearl from mother-of-pearl molluscs in a pharmaceutically acceptable support.

10

2. Pharmaceutical composition according to claim 1, characterized in that the mother-of-pearl molluscs are oysters.

3. Pharmaceutical composition according to claim 2, characterized in that the oysters are oysters of the genus *Pinctada* and more particularly of the genus *Pinctada species margaritifera*.

15

4. Pharmaceutical composition according to any one of the previous claims, characterized in that the pharmaceutically acceptable support is an excipient suitable for topical, enteral or parenteral application.

20

5. Composition according to the previous claim, characterized in that the pharmaceutically acceptable support is an excipient suitable for topical application.

25

6. Composition according to the previous claim, characterized in that the lipids are present at a concentration comprised between 0.02% and 3% by weight, preferably between 0.25% and 2% by weight, and advantageously between 0.5% and 1%, relative to the total weight of the composition.

30

7. Composition according to any one of the previous claims, characterized in that it is intended for the treatment of pathologies involving a decrease in filaggrin activity and/or an increase in membrane transglutaminase activity.

8. Composition according to the previous claim, characterized in that it is intended for the treatment of pathologies related to a decrease in cutaneous filaggrin activity and/or cutaneous overexpression of membrane transglutaminase.

5

9. Composition according to any one of the previous claims, characterized in that it is intended for the treatment of cutaneous pathologies, more particularly selected in the group consisting of psoriasis, ichthyosis and atopic dermatitis.

10 10. Composition according to any one of the previous claims 1 to 8, characterized in that it is intended for the treatment of autoimmune diseases related to an autoimmune reaction to filaggrin, in particular rheumatoid arthritis.

11 11. Composition according to any one of the previous claims 1 to 10, characterized in that it additionally comprises at least one other therapeutically active ingredient for use that is simultaneous, separate or spread out over time.

12 12. Composition according to the previous claim, characterized in that the other therapeutically active ingredient is selected in the group consisting of corticosteroids, coal tar, anthralin, vitamin D3 and derivatives, and retinoids.

13 13. Lipids extracted from the mother of pearl of mother-of-pearl molluscs such as defined according to any one of claims 1 to 3, as a medicament.

25 14. Device comprising lipids such as defined in any one of claims 1 to 3 and a physiologically acceptable excipient.

15 15. Device according to the previous claim, characterized in that it has a form which is adapted to subcutaneous or percutaneous injection, in particular in the form of a syringe or infusion.

30